Lisata Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LSTA research report →
Companywww.lisata.com
Lisata Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.
- CEO
- David J. Mazzo
- IPO
- 1999
- Employees
- 26
- HQ
- Basking Ridge, NJ, US
Price Chart
Valuation
- Market Cap
- $28.96M
- P/E
- -1.75
- P/S
- 170.34
- P/B
- 2.62
- EV/EBITDA
- -0.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.82%
- Op Margin
- -10178.24%
- Net Margin
- -9618.24%
- ROE
- -101.90%
- ROIC
- -157.32%
Growth & Income
- Revenue
- $170.00K · -83.00%
- Net Income
- $-16,586,000 · 17.01%
- EPS
- $-1.91 · 20.42%
- Op Income
- $-18,209,000
- FCF YoY
- 17.46%
Performance & Tape
- 52W High
- $5.07
- 52W Low
- $1.81
- 50D MA
- $4.12
- 200D MA
- $3.10
- Beta
- 0.81
- Avg Volume
- 73.08K
Get TickerSpark's AI analysis on LSTA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 9, 26 | Mazzo David J | other | 81,000 |
| Jan 9, 26 | Mazzo David J | other | 10,503 |
| Jan 9, 26 | Mazzo David J | other | 10,515 |
| Jan 9, 26 | Mazzo David J | other | 12,224 |
| Jan 9, 26 | Mazzo David J | other | 7,854 |
| Jan 9, 26 | Mazzo David J | other | 40,000 |
| Jan 9, 26 | Nisco James | other | 15,000 |
| Jan 9, 26 | Nisco James | other | 2,131 |
| Jan 9, 26 | Nisco James | other | 2,131 |
| Jan 9, 26 | Nisco James | other | 1,137 |
Our LSTA Coverage
We haven't published any research on LSTA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LSTA Report →